IMAB

I MAB (IMAB)

I MAB

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:IMAB

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/06	20:14	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/06/06	20:00	PR Newswire (US)	I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	NASDAQ:IMAB	I MAB
2024/06/05	20:11	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/06/05	20:00	PR Newswire (US)	I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	NASDAQ:IMAB	I MAB
2024/05/31	06:33	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:IMAB	I MAB
2024/05/24	06:11	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/05/24	06:05	GlobeNewswire Inc.	I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024	NASDAQ:IMAB	I MAB
2024/05/22	20:00	PR Newswire (US)	I-Mab to Participate at the Jefferies Global Healthcare Conference	NASDAQ:IMAB	I MAB
2024/04/30	20:00	PR Newswire (US)	I-MAB Filed 2023 Annual Report on Form 20-F	NASDAQ:IMAB	I MAB
2024/04/05	20:00	PR Newswire (US)	I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:IMAB	I MAB
2024/04/03	05:01	PR Newswire (US)	I-Mab Announces Closing of the Divestiture of Business Operations in China	NASDAQ:IMAB	I MAB
2024/03/15	06:00	PR Newswire (US)	I-Mab Reports Full Year 2023 Financial Results and Business Update	NASDAQ:IMAB	I MAB
2024/02/10	06:01	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:IMAB	I MAB
2024/02/08	20:07	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:IMAB	I MAB
2024/02/07	20:52	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/02/07	20:00	PR Newswire (US)	I-Mab Signs Agreement to Divest its Assets and Business Operations in China	NASDAQ:IMAB	I MAB
2024/02/07	10:55	Edgar (US Regulatory)	Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:IMAB	I MAB
2024/02/06	20:34	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
2024/01/05	20:21	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:IMAB	I MAB
2024/01/03	07:08	Dow Jones News	ADRs Slump; FLJ Group Declines 21%	NASDAQ:IMAB	I MAB
2023/12/29	20:12	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:IMAB	I MAB
2023/12/26	20:22	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:IMAB	I MAB
2023/12/02	04:41	Edgar (US Regulatory)	Form SC 13D - General statement of acquisition of beneficial ownership	NASDAQ:IMAB	I MAB
2023/11/16	20:43	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:IMAB	I MAB
2023/11/06	22:00	PR Newswire (US)	I-Mab Announces Participation at Jefferies and Piper Conferences in November	NASDAQ:IMAB	I MAB
2023/11/02	21:00	PR Newswire (US)	Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)	NASDAQ:IMAB	I MAB
2023/11/01	21:00	PR Newswire (US)	I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023	NASDAQ:IMAB	I MAB
2023/10/16	21:00	PR Newswire (US)	I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023	NASDAQ:IMAB	I MAB
2023/10/11	00:04	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:IMAB	I MAB
2023/10/10	21:24	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB